Literature DB >> 2660898

Cytokines regulate the ability of human LAK-cells to kill human tumour cells in vitro.

G Gallagher1, F al-Azzawi, J Davis, W H Stimson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2660898      PMCID： PMC2246747          DOI： 10.1038/bjc.1989.194

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  15 in total

1.  Human antibodies to ovarian cancer antigens secreted by lymphoblastoid cell lines.

Authors:  F Al-Azzawi; W H Stimson; A D Govan
Journal:  J Clin Lab Immunol       Date:  1987-02

Review 2.  Immunotherapy of cancer using interleukin 2: current status and future prospects.

Authors:  S A Rosenberg
Journal:  Immunol Today       Date:  1988-02

Review 3.  Potential impact of immunobiotechnology on cancer therapy.

Authors:  P J Guillou
Journal:  Br J Surg       Date:  1987-08       Impact factor: 6.939

Review 4.  Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes.

Authors:  S A Rosenberg; M T Lotze
Journal:  Annu Rev Immunol       Date:  1986       Impact factor: 28.527

5.  Synergistic antitumor effects of tumor necrosis factor and gamma-interferon on human colon carcinoma cell lines.

Authors:  J H Schiller; G Bittner; B Storer; J K Willson
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

6.  The effects of tumor necrosis factor on the production of interleukin-1 by macrophages.

Authors:  M K Hoffman
Journal:  Lymphokine Res       Date:  1986

7.  Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.

Authors:  T Kalland; H Belfrage; P Bhiladvala; G Hedlund
Journal:  J Immunol       Date:  1987-06-01       Impact factor: 5.422

8.  Interleukin 2-activated human killer cells are derived from phenotypically heterogeneous precursors.

Authors:  N K Damle; L V Doyle; E C Bradley
Journal:  J Immunol       Date:  1986-11-01       Impact factor: 5.422

9.  Interleukin 4 (B cell stimulatory factor 1) can mediate the induction of lymphokine-activated killer cell activity directed against fresh tumor cells.

Authors:  J J Mulé; C A Smith; S A Rosenberg
Journal:  J Exp Med       Date:  1987-09-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307
View more
  2 in total

1.  Lymphokine-activated killer (LAK) cells modulate the effects of IL-2 on a T cell-mediated immune response.

Authors:  P McCulloch; G Gallagher; L P Walsh; Y Zaloom; J Xie
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

2.  Multiple epitopes of the human ovarian cancer antigen 14C1 recognised by human IgG antibodies: their potential in immunotherapy.

Authors:  G Gallagher; F al-Azzawi; L P Walsh; G Wilson; J Handley
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.